[SCHEDULE 13D/A] KalVista Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Frazier-affiliated funds filed Amendment No. 6 to a Schedule 13D for KalVista Pharmaceuticals (KALV) updating beneficial ownership tables and correcting prior attributions. The filing reports specific share counts held directly by several Frazier vehicles: Frazier Life Sciences Public Fund, L.P. (FLSPF) holds 2,400,276 shares (4.8% of class), Frazier Life Sciences Public Overage Fund, L.P. holds 946,074 shares (1.9%), Frazier Life Sciences X, L.P. holds 1,156,869 shares (2.3%), and Frazier Life Sciences XI, L.P. holds 384,648 shares (0.8%). All percentages are calculated using 49,953,739 shares outstanding as of June 25, 2025 per the issuer's annual report.

The amendment clarifies voting and dispositive power: the reported holdings are shared voting/dispositive power for the listed Frazier entities and correct prior over-attributions to individual committee members or managers. It also states that, except as specified, the prior Schedule 13D and amendments remain unchanged and that the filing does not concede beneficial ownership or group status beyond what is expressly stated. A Joint Filing Agreement is referenced as Exhibit 99.1.

Positive

• Clear reconciliation of beneficial ownership figures across multiple Frazier entities, reducing ambiguity for investors
• Specific share counts and percentages provided for each reporting person, with an explicit outstanding share basis (49,953,739)

Negative

• No indication of changes in intentions or proposed actions despite aggregated holdings being material to some investors
• Prior over-attributions required correction, which may have led to earlier misinterpretation of individual influence

Insights

Securities Analyst

TL;DR: Frazier funds collectively disclose meaningful passive stakes in KALV and correct prior beneficial-ownership attributions.

The amendment provides precise share counts and percent-of-class calculations for multiple Frazier vehicles, clarifying that several holdings are subject to shared voting and dispositive power. The correction removing attributed ownership from individual investment committee members reduces potential governance signaling that prior filings may have implied. For investors, the filing documents concentrated positions across related funds (largest single reported holding: 2,400,276 shares, 4.8%). The inclusion of the Joint Filing Agreement confirms coordinated reporting among the entities listed.

Corporate Governance Expert

TL;DR: Amendment focuses on governance attribution corrections, not new activist intentions.

The Schedule 13D/A adjusts which parties are attributed beneficial ownership by clarifying management structures (general partners and investment committees) and removing previous attributions to committee members. This reduces the appearance of individual control while preserving shared powers at the fund level. The filing explicitly disclaims broader admissions of beneficial ownership or ‘‘group’’ status beyond the stated items, which is material for governance interpretation but does not announce a change in control strategy.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

KALVISTA PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

483497103

(CUSIP Number)

Steve R. Bailey
601 Union Street, Suite 3200,
Seattle, WA, 98101
(206) 621-7200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/18/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

Frazier Life Sciences Public Fund, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,400,276.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,400,276.00

11

Aggregate amount beneficially owned by each reporting person

2,400,276.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.8 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

FHMLSP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,400,276.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,400,276.00

11

Aggregate amount beneficially owned by each reporting person

2,400,276.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.8 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

FHMLSP, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,400,276.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,400,276.00

11

Aggregate amount beneficially owned by each reporting person

2,400,276.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.8 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

Frazier Life Sciences Public Overage Fund, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 946,074.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 946,074.00

11

Aggregate amount beneficially owned by each reporting person

946,074.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.9 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

FHMLSP Overage, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 946,074.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 946,074.00

11

Aggregate amount beneficially owned by each reporting person

946,074.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.9 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

FHMLSP Overage, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 946,074.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 946,074.00

11

Aggregate amount beneficially owned by each reporting person

946,074.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.9 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

Frazier Life Sciences X, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,156,869.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,156,869.00

11

Aggregate amount beneficially owned by each reporting person

1,156,869.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

FHMLS X, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,156,869.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,156,869.00

11

Aggregate amount beneficially owned by each reporting person

1,156,869.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

FHMLS X, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,156,869.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,156,869.00

11

Aggregate amount beneficially owned by each reporting person

1,156,869.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

Frazier Life Sciences XI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 384,648.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 384,648.00

11

Aggregate amount beneficially owned by each reporting person

384,648.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

FHMLS XI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 384,648.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 384,648.00

11

Aggregate amount beneficially owned by each reporting person

384,648.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

FHMLS XI, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 384,648.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 384,648.00

11

Aggregate amount beneficially owned by each reporting person

384,648.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

James N. Topper

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,156,869.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,156,869.00

11

Aggregate amount beneficially owned by each reporting person

1,156,869.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The Aggregate Amount represents 1,156,869 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

Patrick J. Heron

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,156,869.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,156,869.00

11

Aggregate amount beneficially owned by each reporting person

1,156,869.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The Aggregate Amount represents 1,156,869 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The Percent of Class is calculated based on 49,953,739 shares of the Issuer's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on July 10, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

Albert Cha

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

James Brush

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 483497103

1

Name of reporting person

Daniel Estes

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.001 par value per share
(b)	Name of Issuer: KALVISTA PHARMACEUTICALS, INC.
(c)	Address of Issuer's Principal Executive Offices: 55 Cambridge Parkway, Suite 901E, Cambridge, MASSACHUSETTS , 02142.
Item 1 Comment: This Amendment No. 6 ("Amendment No. 6") to Schedule 13D amends the statement on Schedule 13D filed on December 30, 2021 (the "Original Schedule 13D") as amended on January 26, 2022, December 30, 2022, December 14, 2023, February 22, 2024 and November 7, 2024 (the "Prior Amendments", and together with the Original Schedule 13D and this Amendment No. 6, the "Schedule 13D"). Except as otherwise specified in Amendment No. 6, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 6 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments.
Item 2.	Identity and Background
(e)
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLSPF directly holds 2,400,276 shares of the Issuer's Common Stock (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Schedule 13D corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLSPOF directly holds 946,074 shares of this Issuer's Common Stock (the "FLSPOF Shares"). FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Schedule 13D corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLS X directly holds 1,156,869 shares of the Issuer's Common Stock (the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares. FLS XI directly holds 384,648 shares of this Issuer's Common Stock (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Schedule 13D corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person.
(b)	The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13D filed on December 30, 2021)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:	08/20/2025

FHMLSP, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:	08/20/2025

FHMLSP, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date:	08/20/2025

Frazier Life Sciences Public Overage Fund, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
Date:	08/20/2025

FHMLSP Overage, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
Date:	08/20/2025

FHMLSP Overage, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Date:	08/20/2025

Frazier Life Sciences X, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:	08/20/2025

FHMLS X, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:	08/20/2025

FHMLS X, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Date:	08/20/2025

Frazier Life Sciences XI, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:	08/20/2025

FHMLS XI, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:	08/20/2025

FHMLS XI, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date:	08/20/2025

James N. Topper

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:	08/20/2025

Patrick J. Heron

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:	08/20/2025

Albert Cha

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:	08/20/2025

James Brush

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:	08/20/2025

Daniel Estes

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022
Date:	08/20/2025

FAQ

How many KALV shares does Frazier Life Sciences Public Fund, L.P. report owning?

The filing reports 2,400,276 shares, equal to 4.8% of KalVista's common stock based on 49,953,739 shares outstanding.

What percentage of KALV does Frazier Life Sciences X, L.P. own?

Frazier Life Sciences X, L.P. holds 1,156,869 shares, which is 2.3% of the class.

Why did the filer submit Amendment No. 6 to the Schedule 13D?

Amendment No. 6 updates the Schedule 13D to correct prior attributions of beneficial ownership and to incorporate the cover-page figures for each reporting person.

Does the amendment signal that these Frazier entities are acting as a group to control KalVista?

The filing states that, except as specified, it should not be construed as an admission that any reporting person is the beneficial owner or a member of a group beyond what is expressly stated.

What document evidences the coordinated filing among the entities?

A Joint Filing Agreement is referenced as Exhibit 99.1 (incorporated by reference to the Schedule 13D filed on December 30, 2021).